Recent Updates
Recently added Catalysts

Olomorasib test

Phase 1

Healthy Volunteers | Small molecule | Other |Eli Lilly and Company|Last Updated: Aug 31, 2026

Target and mechanism

ModalitySmall molecule

Also known as Olomorasib

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment24

FDA Designations

BREAKTHROUGH_THERAPY

Clinical trial landscape

Olomorasib test · 1 trial · 1 indication

Phase 1 1
NCT07794592A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy ParticipantsHealthy Volunteers
NOT YET_RECRUITING24 Analytics
PHASE1NOT YET_RECRUITING
A Study Comparing Two Ways of Taking Olomorasib (LY3537982) in Healthy Participants
Healthy Volunteers
NCT0779459224
Unlock trial analytics

Study Endpoints

Primary Endpoints

Pharmacokinetics: Maximum Concentration (Cmax) of olomorasib
Day 1 to Day 7
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeBASIC_SCIENCE

Treatment Arms

ArmTypeDescription
Olomorasib testEXPERIMENTALOlomorasib administered orally
Olomorasib referenceEXPERIMENTALOlomorasib administered orally

Interventions

NameTypeDescription
Olomorasib testDRUGAdministered orally
Olomorasib referenceDRUGAdministered orally
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 55 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * Have a body mass index (BMI) within the range 18.0 to 30.0 kilograms per square meter (kg/m2) * Participants assigned male at bi...

Countries:United States
Unlock Eligibility Criteria

Recent Changes (Last 90 Days)

LOWAug 31, 2026NCT07794592NEW_TRIAL: changed
LOWAug 31, 2026NCT07794592NEW_TRIAL: changed

Frequently asked questions about Olomorasib test

What is Olomorasib used for?

Olomorasib is an investigational small molecule being developed for non-small cell lung cancer (NSCLC). It is also studied in healthy participants for hepatic insufficiency and general safety trials. The drug is currently in Phase 3 clinical development for NSCLC.

What does Olomorasib target?

Olomorasib targets KRAS G12C mutations. It is being studied in combination with standard of care in participants with resected or unresectable KRAS G12C-mutant non-small cell lung cancer, as shown in the Phase 3 trial NCT06890598.

Who makes Olomorasib?

Olomorasib is developed by Eli Lilly and Company (ticker: LLY). The company is conducting multiple clinical trials for this investigational drug, including a Phase 3 study in non-small cell lung cancer.

What phase is Olomorasib in?

Olomorasib is in Phase 3 clinical development for non-small cell lung cancer. It has received Breakthrough Therapy designation from the FDA. The drug is investigational and not yet approved for any use.

What clinical trials is Olomorasib in?

Olomorasib has three completed Phase 1 trials in healthy participants (NCT07044271, NCT07124013, NCT07439250) and one recruiting Phase 3 trial (NCT06890598) in KRAS G12C-mutant non-small cell lung cancer with 700 participants enrolled.

Is Olomorasib the same as LY3537982?

Yes, Olomorasib is also known as LY3537982. Clinical trial titles refer to the drug as Olomorasib (LY3537982), confirming that both names refer to the same investigational drug.